Prediction of prognosis by markers in community-acquired pneumonia

References

• Mandell LA, Wunderink RG, Anzueto A et al. IDSA/ATS consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2), S27–S72 (2007).
   PubMed Web of Science ®Google Scholar
• Heron M, Hoyert DL, Murphy SL et al. Deaths: final data for 2006. Natl Vital. Stat. Rep. 57, 1–134 (2009).
   PubMedGoogle Scholar
• Almirall J, Bolíbar I, Vidal J et al. Epidemiology of community-acquired pneumonia in adults: a population based study. Eur. Respir. J. 15, 757–763 (2000).
   PubMed Web of Science ®Google Scholar
• Jokinen C, Heiskanen L, Juvonen H et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am. J. Epidemiol. 137, 977–988 (1993).
   PubMed Web of Science ®Google Scholar
• Woodhead M, Blasi F, Ewig S et al. Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections--full version. Clin. Microbiol. Infect. 17(Suppl. 6), E1–59 (2011).
   Google Scholar
• Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2), S27–72 (2007).
   PubMed Web of Science ®Google Scholar
• Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 336, 243–250 (1997).
   PubMed Web of Science ®Google Scholar
• Lim WS, van der Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 58, 377–382 (2009).
   Google Scholar
• Carratalà J, Fernández-Sabé N, Ortega L et al. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann. Intern. Med. 142, 165–172 (2005).
   PubMed Web of Science ®Google Scholar
• Huang DT, Weissfeld LA, Kellum JA et al.; GenIMS Investigators. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann. Emerg. Med. 52, 48–58 (2008).
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Mandal P, Singanayagam A et al. Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med. 37, 1409–1420 (2011).
   PubMed Web of Science ®Google Scholar
• Mayeux R. Biomarkers: Potential Uses and Limitations. NeuroRx. 1, 182–188 (2004).
   PubMedGoogle Scholar
• Naylor S. Biomarkers: current perspectives and future prospects. Expert. Rev. Mol. Diagn. 3, 525–529 (2003).
   PubMed Web of Science ®Google Scholar
• Rosón B, Carratalà J, Dorca J et al. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin. Infect. Dis. 33, 158–165 (2001).
   PubMed Web of Science ®Google Scholar
• Blasi F, Garau J, Medina J, Avila M, McBride K, Ostermann H. Current management of patients hospitalized with community-acquired pneumonia across Europe: outcomes from REACH. Respir. Res. 14, 44 (2013).
   Google Scholar
• Rodriguez A, Lisboa T, Blot S et al. Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. Intensive Care Med. 35, 430–438 (2009).
   PubMed Web of Science ®Google Scholar
• Bruns AH, Oosterheert JJ, Cucciolillo MC et al. Cause-specific long-term mortality rates in patients recovered from community-acquired pneumonia as compared with the general Dutch population. Clin. Microbiol. Infect. 17, 763–768 (2011).
   PubMed Web of Science ®Google Scholar
• Reade MC, Yende S, D’Angelo G et al.; Genetic and Inflammatory Markers of Sepsis Investigators. Differences in immune response may explain lower survival among older men with pneumonia. Crit. Care Med. 37, 1655–1662 (2009).
   PubMedGoogle Scholar
• Lim WS, Baudouin SV, George RC et al. Pneumonia Guidelines Committee of the BTS Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 64 (Suppl. 3), iii1–iii55 (2009).
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Singanayagam A, Akram AR et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax. 65, 878–883 (2010).
   PubMed Web of Science ®Google Scholar
• Narvaez-Rivera RM, Rendon A, Salinas-Carmona MC, Rosas-Taraco AG. Soluble RAGE as a severity marker in community acquired pneumonia associated sepsis. BMC Infect. Dis. 12, 15 (2012).
   PubMed Web of Science ®Google Scholar
• Viasus D, Garcia-Vidal C, Simonetti A et al. Prognostic value of serum albumin levels in hospitalized adults with community-acquired pneumonia. J. Infect. 66, 415–423 (2013).
   PubMed Web of Science ®Google Scholar
• van de Garde EM, Endeman H, Deneer VH et al. Angiotensin-converting enzyme (ACE) I/D corrected serum ACE activity and severity assessment of community-acquired pneumonia. Clin. Chem. Lab. Med. 45, 1326–1331 (2007).
   PubMedGoogle Scholar
• Meijvis SC, Cornips MC, Endeman H et al. Prognostic value of serum angiotensin-converting enzyme activity for outcome of community-acquired pneumonia. Clin. Chem. Lab. Med. 49, 1525–1532 (2011).
   PubMedGoogle Scholar
• Jeong KY, Kim K, Kim TY et al. Prognostic value of N-terminal pro-brain natriuretic peptide in hospitalised patients with community-acquired pneumonia. Emerg. Med. J. 28, 122–127 (2011).
   PubMedGoogle Scholar
• Snijders D, Schoorl M, Schoorl M, Bartels PC, van der Werf TS, Boersma WG. D-dimer levels in assessing severity and clinical outcome in patients with community-acquired pneumonia. A secondary analysis of a randomised clinical trial. Eur. J. Intern. Med. 23, 436–441 (2012).
   PubMedGoogle Scholar
• Huang DT, Angus DC, Kellum JA et al. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest. 136, 823–831 (2009).
   PubMed Web of Science ®Google Scholar
• Hu W, Liu CW, Su J, Lu J, Zhu Y, Liu BW. Elevated plasma visfatin concentrations in patients with community-acquired pneumonia. Peptides. 43, 8–12 (2013).
   PubMedGoogle Scholar
• Suberviola B, Castellanos-Ortega A, Llorca J, Ortiz F, Iglesias D, Prieto B. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia. Swiss. Med. Wkly 142, w13542 (2012).
   PubMed Web of Science ®Google Scholar
• Courtais C, Kuster N, Dupuy AM et al. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia. Am. J. Emerg. Med. 31, 215–221 (2013).
   PubMed Web of Science ®Google Scholar
• Schuetz P, Wolbers M, Christ-Crain M et al. ProHOSP Study Group. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit. Care 14, R106 (2010).
   Google Scholar
• Schuetz P, Christ-Crain M, Zimmerli W, Mueller B. Repeated measurements of endothelin-1 precursor peptides predict the outcome in community-acquired pneumonia. Intensive Care Med. 37, 970–980 (2011).
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am. J. Med. 121, 219–225 (2008).
   PubMed Web of Science ®Google Scholar
• Menéndez R, Martínez R, Reyes S et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax. 64, 587–591 (2009).
   PubMed Web of Science ®Google Scholar
• Lin WC, Lu SL, Lin CF et al. Plasma kallistatin levels in patients with severe community-acquired pneumonia. Crit. Care. 17, R27 (2013).
   Google Scholar
• Brogly N, Devos P, Boussekey N, Georges H, Chiche A, Leroy O. Impact of thrombocytopenia on outcome of patients admitted to ICU for severe community-acquired pneumonia. J. Infect. 55, 136–140 (2007).
   PubMedGoogle Scholar
• Salluh JI, Rabello LS, Rosolem MM et al. The impact of coagulation parameters on the outcomes of patients with severe community-acquired pneumonia requiring intensive care unit admission. J. Crit. Care. 26, 496–501 (2011).
   PubMed Web of Science ®Google Scholar
• Boussekey N, Leroy O, Alfandari S, Devos P, Georges H, Guery B. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med. 32, 469–472 (2006).
   PubMed Web of Science ®Google Scholar
• Coelho LM, Salluh JI, Soares M et al. Patterns of C-reactive protein RATIO response in severe community-acquired pneumonia: a cohort study. Crit. Care. 16, R53 (2012).
   PubMed Web of Science ®Google Scholar
• Salluh JI, Bozza FA, Soares M et al. Adrenal response in severe community-acquired pneumonia: impact on outcomes and disease severity. Chest. 134, 947–954 (2008).
   PubMed Web of Science ®Google Scholar
• Yende S, D’Angelo G, Mayr F et al.; GenIMS Investigators. Elevated hemostasis markers after pneumonia increases one-year risk of all-cause and cardiovascular deaths. PLoS One. 6, e22847 (2011).
   Google Scholar
• Braun E, Domany E, Kenig Y, Mazor Y, Makhoul BF, Azzam ZS. Elevated red cell distribution width predicts poor outcome in young patients with community acquired pneumonia. Crit. Care. 15, R194 (2011).
   PubMed Web of Science ®Google Scholar
• Guertler C, Wirz B, Christ-Crain M, Zimmerli W, Mueller B, Schuetz P. Inflammatory responses predict long-term mortality risk in community-acquired pneumonia. Eur. Respir. J. 37, 1439–1446 (2011).
   PubMed Web of Science ®Google Scholar
• Krüger S, Ewig S, Kunde J, Hartmann O, Suttorp N, Welte T; CAPNETZ Study Group. Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in community-acquired pneumonia: results from the German Competence Network CAPNETZ. Thorax 65, 208–214 (2010).
   PubMed Web of Science ®Google Scholar
• Nowak A, Breidthardt T, Christ-Crain M et al. Direct comparison of three natriuretic peptides for prediction of short- and long-term mortality in patients with community-acquired pneumonia. Chest 141, 974–982 (2012).
   PubMedGoogle Scholar
• Bello S, Lasierra AB, Mincholé E et al. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. Eur. Respir. J. 39, 1144–1155 (2012).
   PubMed Web of Science ®Google Scholar
• Bauer MP, Hensgens MP, Miller MA et al. Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis. Clin. Infect. Dis. 55(Suppl, 2), S149–153 (2012).
   PubMed Web of Science ®Google Scholar
• Thiem U, Niklaus D, Sehlhoff B et al. C-reactive protein, severity of pneumonia and mortality in elderly, hospitalised patients with community-acquired pneumonia. Age Ageing 38, 693–697 (2009).
   PubMedGoogle Scholar
• Steyerberg EW, Pencina MJ, Lingsma HF, Kattan MW, Vickers AJ, Van Calster. Assessing the incremental value of diagnostic and prognostic markers: a review and illustration. Eur. J. Clin. Invest. 42, 216–228 (2012).
   PubMed Web of Science ®Google Scholar
• Marrie TJ, Shariatzadeh MR. Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study. Medicine (Baltimore). 86, 103–111 (2007).
   PubMed Web of Science ®Google Scholar
• Brown SM, Jones JP, Aronsky D, Jones BE, Lanspa MJ, Dean NC. Relationships among initial hospital triage, disease progression and mortality in community-acquired pneumonia. Respirology. 17, 1207–1213 (2012).
   PubMed Web of Science ®Google Scholar
• Phua J, Ngerng WJ, Lim TK. The impact of a delay in intensive care unit admission for community-acquired pneumonia. Eur. Respir. J. 36, 826–833 (2010).
   PubMed Web of Science ®Google Scholar
• Charles PG, Wolfe R, Whitby M et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin. Infect. Dis. 47, 375–384 (2008).
   PubMed Web of Science ®Google Scholar
• Renaud B, Labarère J, Coma E et al. Risk stratification of early admission to the intensive care unit of patients with no major criteria of severe community-acquired pneumonia: development of an international prediction rule. Crit. Care. 13, R54 (2009).
   PubMed Web of Science ®Google Scholar
• Ramírez P, Ferrer M, Martí V et al. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit. Care Med. 39, 2211–2217 (2011).
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Morgenthaler NG, Stolz D et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia. Crit. Care 10, R96 (2006).
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Singanayagam A, Scally C, Hill AT. Admission D-dimer can identify low-risk patients with community-acquired pneumonia. Ann. Emerg. Med. 53, 633–638 (2009).
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am. J. Med. 121, 219–225 (2008).
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim J, Kim K et al. Albumin and C-reactive protein have prognostic significance in patients with community-acquired pneumonia. J. Crit. Care. 26, 287–294 (2011).
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Taylor JK, Mandal P et al. Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin. Infect. Dis. 53, 503–511 (2011).
   PubMed Web of Science ®Google Scholar
• Renaud B, Schuetz P, Claessens YE, Labarère J, Albrich W, Mueller B. Proadrenomedullin improves Risk of Early Admission to ICU score for predicting early severe community-acquired pneumonia. Chest 142, 1447–1454 (2012).
   PubMed Web of Science ®Google Scholar
• Halm EA, Fine MJ, Marrie TJ et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 279, 1452–1457 (1998).
   PubMed Web of Science ®Google Scholar
• Oosterheert JJ, Bonten MJM, Schneider MME et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ. 333, 1193 (2006).
   PubMedGoogle Scholar
• Carratalà J, Garcia-Vidal C, Ortega L et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. Arch. Intern. Med. 172, 922–928 (2012).
   PubMedGoogle Scholar
• Garcia-Vidal C, Carratalà J. Early and late treatment failure in community-acquired pneumonia. Semin. Respir. Crit. Care Med. 30, 154–160 (2009).
   PubMed Web of Science ®Google Scholar
• Menéndez R, Cavalcanti M, Reyes S et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax. 63, 447–452 (2008).
   PubMed Web of Science ®Google Scholar
• Kolditz M, Halank M, Schulte-Hubbert B, Bergmann S, Albrecht S, Höffken G. Copeptin predicts clinical deterioration and persistent instability in community-acquired pneumonia. Respir. Med. 106, 1320–1328 (2012).
   PubMed Web of Science ®Google Scholar
• Menéndez R, Martinez R, Reyes S et al. Stability in community-acquired pneumonia: one step forward with markers? Thorax 64, 987–992 (2009).
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Breidthardt T, Stolz D, et al. Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia. J. Intern. Med. 264, 166–176 (2008).
   PubMed Web of Science ®Google Scholar
• Müller B, Morgenthaler N, Stolz D et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur. J. Clin. Invest. 37, 145–152 (2007).
   PubMed Web of Science ®Google Scholar
• Albrich WC, Dusemund F, Rüegger K et al. Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC Infect. Dis. 11, 112 (2011).
   PubMed Web of Science ®Google Scholar
• Levy MM, Fink MP, Marshall JC, Abraham E et al.; SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 31, 1250–1256 (2003).
   PubMed Web of Science ®Google Scholar
• Rello J, Rodriguez A, Lisboa T, Gallego M, Lujan M, Wunderink R. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit. Care Med. 37, 456–462 (2009).
   PubMed Web of Science ®Google Scholar
• Waterer GW. Community-acquired pneumonia: genomics, epigenomics, transcriptomics, proteomics, and metabolomics. Semin. Respir. Crit. Care Med. 33, 257–265 (2012).
   PubMedGoogle Scholar
• Lee JH, Chung HJ, Kim K et al. Red cell distribution width as a prognostic marker in patients with community-acquired pneumonia. Am. J. Emerg. Med. 31, 72–79 (2013).
   PubMed Web of Science ®Google Scholar
• Kolditz M, Höffken G, Martus P et al.; CAPNETZ study group. Serum cortisol predicts death and critical disease independently of CRB-65 score in community-acquired pneumonia: a prospective observational cohort study. BMC Infect. Dis. 12, 90 (2012).
   PubMed Web of Science ®Google Scholar
• Horie M, Ugajin M, Suzuki M et al. Diagnostic and prognostic value of procalcitonin in community-acquired pneumonia. Am. J. Med. Sci. 343, 30–35 (2012).
   PubMedGoogle Scholar
• Park JH, Wee JH, Choi SP, Oh SH. The value of procalcitonin level in community-acquired pneumonia in the ED. Am. J. Emerg. Med. 30, 1248–1254 (2012).
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim J, Kim K et al. Albumin and C-reactive protein have prognostic significance in patients with community-acquired pneumonia. J. Crit. Care. 26, 287–294 (2011).
   PubMed Web of Science ®Google Scholar
• Mirsaeidi M, Peyrani P, Aliberti S et al. Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia. Chest. 137, 416–420 (2010).
   PubMed Web of Science ®Google Scholar
• Mueller C, Laule-Kilian K, Scholer A, Perruchoud AP. B-type natriuretic peptide for risk stratification in community-acquired pneumonia. J. Intern. Med. 258, 391–393 (2005).
   PubMed Web of Science ®Google Scholar
• Müller B, Morgenthaler N, Stolz D et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur. J. Clin. Invest. 37, 145–152 (2007).
   PubMed Web of Science ®Google Scholar
• Krüger S, Ewig S, Marre R et al.; CAPNETZ Study Group. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur. Respir. J. 31, 349–355 (2008).
   PubMed Web of Science ®Google Scholar
• Masiá M, Papassotiriou J, Morgenthaler NG, Hernández I, Shum C, Gutiérrez F. Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia. Clin. Chem. 53, 2193–2201 (2007).
   PubMed Web of Science ®Google Scholar
• Krüger S, Ewig S, Kunde J, Hartmann O, Suttorp N, Welte T; CAPNETZ Study Group. Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in community-acquired pneumonia: results from the German Competence Network CAPNETZ. Thorax 65, 208–214 (2010).
   PubMed Web of Science ®Google Scholar
• Remmelts HH, van de Garde EM, Meijvis SC et al. Addition of vitamin D status to prognostic scores improves the prediction of outcome in community-acquired pneumonia. Clin. Infect. Dis. 55, 1488–1494 (2012).
   PubMed Web of Science ®Google Scholar